Shahin Jamal

Clinician Investigator, MD, FRCPC, MSc

 

Appointments

  • Department of Medicine, Division of Rheumatology at Vancouver Coastal Health
  • Clinical Associate Professor at the University of British Columbia and Program Director of Adult Rheumatology
  • Coordinator of the Clinical Review Course of the Canadian Rheumatology Association (CRA)

Research Interests

  • Diagnosis and prognosis of early inflammatory arthritis
  • Timely assessment and access to care for patients with rheumatoid arthritis
  • Rheumatologic immune mediated adverse events associated with immunotherapy in oncology

Dr. Shahin Jamal completed a Bachelor’s Degree in Physical Therapy at McGill University. She obtained her Doctor of Medicine from the University of British Columbia in 1999, completed her Internal Medicine residency training at Queens University in 2002 and Rheumatology training at the University of Toronto in 2004. She went on to obtain her Masters Degree in Clinical Epidemiology at the University of Toronto in 2007. Her thesis work focused on the delays in treatment for patients with rheumatoid arthritis and barriers to care. She completed the Clinical Investigator Program with the Royal College of Physicians and Surgeons of Canada in 2007.

Learn more

Dr. Jamal was awarded a Canadian Arthritis Society Clinical Fellowship from 2002 to 2004.  She received a Canadian Arthritis Network Post Doctoral Fellowship Award from 2005 to 2007 and a Canadian Society Research Fellowship from 2005 to 2008. In September 2013, she received the Arthritis Society Clinician Teacher/Educator Award.

 

Currently, Dr. Jamal is an active staff physician in the Department of Medicine, Division of Rheumatology at Vancouver Coastal Health. She is Clinical Associate Professor at the University of British Columbia and Program Director of Adult Rheumatology.  She is past-chair of the Guidelines Committee of the Canadian Rheumatology Association (CRA) and is coordinator of the Clinical Review Course of the CRA. Her interests include diagnosis and prognosis of early inflammatory arthritis, timely assessment and access to care for patients with rheumatoid arthritis, and rheumatologic immune mediated adverse events associated with immunotherapy in oncology.